RxDoctor Payments Data

Benjamin Walsh, MD

Family Medicine · Crossett, ARNPI 1497735609

Payments from drug & device makers

$712in general payments, 2019–2025

Across 37 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$238
  • Smith+Nephew$144
  • Merck$107
  • Lilly USA, LLC$64
  • AbbVie$36
  • Amgen$30
  • plus $93 from 6 others

What the payments were for

  • Food & beverage$712100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$712 in reported general payments places this provider in the 50th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$149,381
Medicare patients
382
Services billed
3,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$88,281
EliquisApixaban80$64,725
Tresiba Flextouch U-200Insulin Degludec59$49,293
JardianceEmpagliflozin56$46,119
EntrestoSacubitril/Valsartan15$13,095
XareltoRivaroxaban15$12,516
FarxigaDapagliflozin Propanediol11$12,249
RybelsusSemaglutide12$10,279
Spiriva RespimatTiotropium Bromide11$7,080
BrilintaTicagrelor12$5,584
Atorvastatin Calcium692$4,982
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,189
Gabapentin271$3,795
Potassium Chloride258$3,577
Omeprazole343$3,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$238$98,559102 claims
PfizerEliquis$20$64,72580 claims
Boehringer IngelheimJardiance, Spiriva Respimat$13$53,19967 claims
Johnson & JohnsonXarelto$15$12,51615 claims
AbbVieSynthroid$36$1,28923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Crossett

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →